Sichenzia Ross Friedman Ference LLP Advises Citius Pharmaceuticals, LLC on a Reverse Merger and $2.04 Million Pipe Financing
September 18, 2014 (GLOBE NEWSWIRE) – New York – based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Citius Pharmaceuticals, LLC (OTCQB: CTXR) – a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets- in connection with a Share Exchange and Reorganization Agreement between Citius Pharmaceuticals, LLC, Citius Pharmaceuticals, Inc. (formerly known as Trail One. Inc.) and the beneficial holders of the membership interests of Citius.
Pursuant to the “Exchange Agreement”, Citius Pharmaceuticals, Inc. issued common stock to the holders of the membership interests of Citius representing approximately 72.0% of the outstanding shares of common stock.
In connection with the “Exchange Agreement”, Sichenzia Ross advised Citius on a private offering whereby Citius sold 3,4000,067 Units for a purchase price of $0.60 per Unit for a total value of $2.04 million. Each Unit sold consisted of one share of common stock and a five-year warrant. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia and Arthur S. Marcus.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Quest Solutions, Inc. in $5 Million Private Placement - April 10, 2019
- Sichenzia Ross Ference LLP Congratulates INmune Bio Inc., on Initial Public Offering - April 10, 2019
- FDA sets first hearing on CBD in May as the agency looks at legalizing the cannabis compound in food and drinks - April 4, 2019